Skip to main
VYGR
VYGR

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is well-positioned for long-term revenue growth through its co-commercialization options for key gene therapy programs, which could substantiate the clinical efficacy of its advanced TRACER platform. The company's robust pipeline, featuring innovative therapies for neurological diseases, includes promising candidates like the anti-tau antibody and SOD1 silencing gene therapy, which may lead to significant value creation for shareholders. Additionally, Voyager’s extended cash runway into mid-2027, following strategic decisions to prioritize its Alzheimer’s programs, alongside a favorable safety profile evidenced by the absence of serious adverse events, supports a positive outlook for the company's financial prospects.

Bears say

Voyager Therapeutics Inc faces significant financial risks as it is currently not generating sales revenue, and projections indicate that it may take several years before the company achieves profitability, as evidenced by a reported net loss of ($1.13) per share. There are also considerable uncertainties surrounding clinical trials, including the potential for delays, failures in demonstrating efficacy, and the challenges posed by competition from other advanced tau antibody programs, which could hinder Voyager's market positioning. Regulatory risks further compound the negative outlook, as there is a reliance on VY7523 and other therapies receiving FDA and EMA approvals by 2033 and 2034, respectively, amidst concerns over the overall safety and efficacy of these candidates in clinical settings.

Voyager Therapeutics (VYGR) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 20 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.